Alvotech ( NASDAQ: ALVO ) and Dr. Reddy’s Laboratories SA ( NYSE: RDY ) announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). Dr.
Reddy’s gets exclusive commercialization rights in the United States as well as semi-exclusive rights in Europe and United Kingdom Alvotech will be responsible for development and manufacturing of the product. Source: Press Release More on Alvotech, Dr. Reddy's, etc.
Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Teva, Alvotech launch biosimilar against AbbVie’s Humira Alvotech to produce Humira biosimilar for Cigna's Quallent.